BWX Technologies misses second quarter revenue but beats EPS, raising full-year 2026 guidance.

BWX Technologies reported second quarter 2026 revenue of $901.6 million, an 18% increase year-over-year, and non-GAAP EPS of $1.07. The company announced the sale of its medical business and raised its full-year 2026 financial guidance, citing strong first-half performance and contributions from its recent acquisition of Precision Components Group.

Key Highlights

• Commercial Operations revenue surged 72% year-over-year to $302.5 million, driven by growth in commercial nuclear components, field services, and medical isotopes.
• The company raised its full-year 2026 guidance, now expecting non-GAAP EPS between $4.70 and $4.80 (up from $4.60 - $4.75) and adjusted EBITDA between $662 million and $672 million (up from $650 - $665 million).
• BWXT announced the sale of its medical business to increase focus on its core nuclear national defense and commercial nuclear power markets.